NCARDIA
Ncardia is an Operator of a biotechnology company intended to expedite drug discovery and development process.The company uses hiPSC stem cell technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates as well as enhance cardiovascular and neural drug screening, enabling researchers to bring predictive human disease biology and accelerate drug discovery.
NCARDIA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2010-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.ncardia.com
Total Employee:
11+
Status:
Active
Contact:
(310) 713-3222
Email Addresses:
[email protected]
Total Funding:
83.72 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Global Site Tag Mobile Non Scaleable Content Nginx
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Employees Featured
Founder
Investors List
KINICITI
KINICITI investment in Venture Round - Ncardia
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Ncardia
Sambrinvest
Sambrinvest investment in Series B - Ncardia
InnovationQuarter
InnovationQuarter investment in Series B - Ncardia
S.R.I.W.
S.R.I.W. investment in Series B - Ncardia
SFPI-FPIM
SFPI-FPIM investment in Series B - Ncardia
Epimède SA
Epimède SA investment in Series B - Ncardia
SFPI-FPIM
SFPI-FPIM investment in Venture Round - Ncardia
Sambrinvest
Sambrinvest investment in Venture Round - Ncardia
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Ncardia
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-24 | Ncardia Appoints Andy Holt as Chief Commercial Officer |
Official Site Inspections
http://www.ncardia.com Semrush global rank: 4.52 M Semrush visits lastest month: 2.34 K
- Host name: 199.60.103.119
- IP address: 199.60.103.119
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "Ncardia" on Search Engine
Ncardia | LinkedIn
Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America.See details»
Ncardia - Crunchbase Company Profile & Funding
Ncardia is an Operator of a biotechnology company intended to expedite drug discovery and development process. Leiden, Zuid-Holland, The Netherlands. 51-100. Venture - …See details»
Press release: Ncardia launches Cellistic, an iPSC …
Apr 14, 2022 Ncardia has launched a new business, Cellistic TM to focus Ncardia’s induced pluripotent stem cell (iPSC) expertise on the cell therapy development and manufacturing sector. This strategy expands on …See details»
Press release: Ncardia Secures $60+ Million to …
Nov 15, 2021 Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. Ncardia is built on the belief that stem cell technology will help …See details»
Ncardia inks $60M funding deal to expand discovery and …
By Kyle LaHucik Nov 16, 2021 7:40am. funding induced pluripotent stem cells strategic partnership Ncardia. Ncardia, a human-induced pluripotent stem cell developer, picked …See details»
Preclinical CRO Ncardia emerges with $12.42m in financing and …
Dec 7, 2017 Ncardia is ‘moving up the value chain’ as it shifts from a product-focused company to a preclinical contract research organization (CRO) and grows in size – and …See details»
Ncardia Secures $60+ Million to Enhance and Expand Leading …
Nov 16, 2021 Ncardia is a human iPSC technology company that operates worldwide with facilities, offices, and staff throughout Europe and North America. Ncardia is built on the …See details»
Quell Therapeutics and Cellistic™ enter a strategic collaboration …
Apr 27, 2022 About Ncardia. Ncardia is a leader in contract research, development and manufacture of iPSC-based solutions for early and preclinical drug discovery. Its goal is …See details»
Ncardia - Funding, Financials, Valuation & Investors - Crunchbase
Ncardia has raised a total of. $83.7M. in funding over 5 rounds. Their latest funding was raised on Nov 16, 2021 from a Venture - Series Unknown round. Ncardia is funded by 8 …See details»
Ncardia Launches Cellistic™, the Only iPSC-based Cell Therapy …
Apr 19, 2022 Ncardia is a leader in contract research, development and manufacture of iPSC-based solutions for early and preclinical drug discovery. Its goal is to enable …See details»
Discovery Services by Ncardia - Established Cell Models
Bringing human biology to hit identification, hit to lead or lead optimization stages is possible with Ncardia's iPSC technology and expertise. Ncardia cell models merge high …See details»
Cell therapy weekly: Ncardia launches iPSC-based cell therapy ...
21 Apr 2022. Written by Harriet Stanwix. CAR-T Cell therapy Clinical manufacturing FDA iPSCs News News round-up US and Canada. This week: Ncardia launched a new …See details»
Ncardia - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Ncardia. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 3. Contacts 30. About. …See details»
Ncyte® vCardiomyocytes by Ncardia
Ncyte ® vCardiomyocytes exhibit well aligned myofibrils and intact structural sarcomere organization (See figure A). They typically express Myosin Light Chain 2v (MLC2v), …See details»
Ucardia | The Heart of What Matters
Heart Health. Reimagined. Everyone's cardiac journey is unique. Ucardia meets you where you are. Get In Touch. Ucardia offers an unparalleled combination of cardiac wellness …See details»